Pharmaceutical Innovation Versus Generic Competition - In the Context of the New EU Pharmaceutical Legislation
Development of innovative drugs is a lengthy, risky and expensive enterprise, and the research-based pharmaceutical industry depends uniquely on intellectual property rights, e.g. patents and regulatory data protection to support its investments in drug development activities. After the expiry of intellectual property rights for original drugs, generic drugs may enter the market. A generic drug is
